Katy Beckermann
@katybeckermann.bsky.social
GU medical oncologist, clinical trialist, mother, wife, runner, avid reader, enjoy traveling.
Reposted by Katy Beckermann
Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC @ascocancer.bsky.social #GU25
www.onclive.com/view/lenvati...
www.onclive.com/view/lenvati...
Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC
Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.
www.onclive.com
February 15, 2025 at 7:08 PM
Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC @ascocancer.bsky.social #GU25
www.onclive.com/view/lenvati...
www.onclive.com/view/lenvati...